NYSE - Nasdaq Real Time Price USD

Thermo Fisher Scientific Inc. (TMO)

697.00 -12.18 (-1.72%)
At close: 30 October at 4:00:02 pm GMT-4
696.18 -0.82 (-0.12%)
After hours: 30 October at 7:00:28 pm GMT-4
Chart Range Bar
Loading chart for TMO
  • Previous close 709.18
  • Open 710.69
  • Bid 695.24 x 8000
  • Ask 697.90 x 8000
  • Day's range 691.74 - 711.79
  • 52-week range 435.27 - 711.85
  • Volume 2,089,151
  • Avg. Volume 2,090,140
  • Market cap (intra-day) 258.25B
  • Beta (5Y monthly) 0.88
  • PE ratio (TTM) 36.76
  • EPS (TTM) 18.96
  • Earnings date (est.) 28 Jan 2027
  • Forward dividend & yield 1.88 (0.27%)
  • Ex-dividend date 15 Sept 2026
  • 1y target est 752.12

Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services internationally. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. The Life Sciences Solutions segment includes reagents, instruments, and consumables for biological and medical research; discovery and production of drugs and vaccines; and diagnosis of infections and diseases. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The Specialty Diagnostics segment offers clinical diagnostics products, such as liquid ready-to-use and lyophilized immunodiagnostic reagent kits, calibrators, controls, protein detection assays, and instruments; immunodiagnostic offerings comprising developing, manufacturing, and marketing of complete blood-test systems for the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; microbiology offerings, such as dehydrated and prepared culture media, collection and transport systems, instrumentation and consumables to detect pathogens in blood, diagnostic and rapid direct specimen tests, quality-control products, and associated products; transplant diagnostics products, including human leukocyte antigen typing and testing for the organ transplant market; and healthcare market channel offerings. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.

www.thermofisher.com

125,000

Full-time employees

31 December

Fiscal year ends

Healthcare

Sector

Diagnostics & Research

Industry

Recent news

View more

Performance overview

Trailing total returns as of 30/10/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD return

TMO
20.62%
S&P 500 (^GSPC)
10.73%

1-year return

TMO
25.75%
S&P 500 (^GSPC)
11.11%

3-year return

TMO
62.12%
S&P 500 (^GSPC)
81.91%

5-year return

TMO
11.68%
S&P 500 (^GSPC)
64.59%

Earnings trends

View more

Earnings per share

GAAP
Normalised
GAAP
Normalised
 

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q3 FY26
Revenue 12.14B
Earnings 1.72B
Profit margin 14.18%

Q4

FY25

Q1

FY26

Q2

FY26

Q3

FY26

0
2B
4B
6B
8B
10B
12B
14.5%
15.0%
15.5%
16.0%
 

Analyst insights

View more

Analysts' price targets

590.00 Low
752.12 Average
697.00 Current
830.00 High
 

Analyst recommendations

  • Strong buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Latest rating

Date 30/10/2026
Analyst Argus Research
Rating action Maintains
Rating Buy
Price action Raises
Price target 560 -> 780
 

Statistics

View more

Valuation measures

As of 30/10/2026
  • Market cap

    258.25B

  • Enterprise value

    293.69B

  • Trailing P/E

    36.76

  • Forward P/E

    25.22

  • PEG ratio (current)

    17.20

  • Price/sales (ttm)

    5.50

  • Price/book (mrq)

    4.72

  • Enterprise value/revenue

    6.20

  • Enterprise value/EBITDA

    25.34

Financial highlights

Profitability and income statement

  • Profit margin

    14.94%

  • Return on assets (ttm)

    5.23%

  • Return on equity (ttm)

    13.38%

  • Revenue (ttm)

    47.35B

  • Net income avi to common (ttm)

    7.07B

  • Diluted EPS (ttm)

    18.96

Balance sheet and cash flow

  • Total cash (mrq)

    6.06B

  • Total debt/equity (mrq)

    75.36%

  • Levered free cash flow (ttm)

    6.45B

Compare

Select to analyse similar companies using key performance metrics; select up to four stocks.

People also watch